English (UK)
中文版Frank Lai
biotech company with 18 years technological accumulation. mature technology platform for monoclonal antibody,recombinant protein,vaccine etc. own significant cost competitiveness advantage
sinocelltech sinobiological
BD directorJoe Lai
Fosun Hani Securities Limited is a wholly-owned subsidiary of Fosun International Limited (HKEx: 00656), a leading global investment group (Fosun Group).
Fosun Hani Securities is Fosun Group's integrated financial hub and primary investment arm in Hong Kong. Established in 1995, Fosun Hani Securities is a participant member of The Stock Exchange of Hong Kong Limited (Broker No. 0820 and 0829).
Fosun Hani Securities is Fosun Group's integrated financial hub and primary investment arm in Hong Kong. Established in 1995, Fosun Hani Securities is a participant member of The Stock Exchange of Hong Kong Limited (Broker No. 0820 and 0829).
Fosun
Managing DirectorJames Lee
Leading business development strategy consulting firm, assisting clients in the pharmaceutical, biotech and healthcare investment industries for more than 25 years.
Three core lines of business, each focused on helping companies build and strengthen development.
Three core lines of business, each focused on helping companies build and strengthen development.
Cello Health BioConsulting
Principal, Oncology LeadTong Lee
A clinical-stage US pharma company with a P2B asset (US FDA IND) targeted for multiple substance use disorders and stressor-related disorders (e.g., PTSD) with unmet medical needs.
Generys
CEOGordon Lee
Dawn Biopharmaceuticals Inc (DBI) is a US firm founded by Gordon Lee, MD (UK MBChB), MBA (Wharton) who has access to a proprietary cell-based immunotherapeutic product for clinical development in the US. The product is a multivalent cancer therapy that integrates multiple anti-cancer mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses a therapeutic cytokine in the cancer - but not systemically.
(Please note that the website is pending.)
(Please note that the website is pending.)
Dawn Biopharmaceuticals Inc.
FounderDr. Won Sik Lee
Idience Co. Ltd. (“Idience’) is a NRDO (No Research & Development Only) company focusing on oncology treatment. The company was established in 2019 by Ildong Holdings Group, a holding company of leading pharmaceutical and healthcare companies in South Korea.
Our first asset, IDX-1197 is a PARP inhibitor for various solid cancers including breast cancer and ovarian cancer. Its ongoing Phase 1a multi-center study showed a promising result. In October 2019, Idience received approval for its initial Investigational New Drug (IND) application from the Korea Ministry of Food and Drug Safety to start a Phase 1b/2a clinical trial for IDX-1197.
Idience is looking for corporate partners to discover and develop oncology therapeutics. We are open to all license-in and license-out partners.
Our first asset, IDX-1197 is a PARP inhibitor for various solid cancers including breast cancer and ovarian cancer. Its ongoing Phase 1a multi-center study showed a promising result. In October 2019, Idience received approval for its initial Investigational New Drug (IND) application from the Korea Ministry of Food and Drug Safety to start a Phase 1b/2a clinical trial for IDX-1197.
Idience is looking for corporate partners to discover and develop oncology therapeutics. We are open to all license-in and license-out partners.
Responsive Web Design powered by 